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MODELING THE IMPACT OF TECHNOLOGY DIFFUSION IN BREAST 
CANCER TREATMENT ON THE COST-EFFECTIVENESS OF 
MAMMOGRAPHY SCREENING
Shih YCT1, Venier J1, Munsell M1, Cantor SB1, Elting LS1, Ravdin P2, Berry DA1
1University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2Adjuvant! Online, 
San Antonio, TX, USA
OBJECTIVES: The association between treatment advances and dissemination and 
the cost-effectiveness of cancer screening is largely unknown. This study addressed the 
above association among breast cancer patients. METHODS: Using a Bayesian micro-
simulation model, we followed a hypothetical cohort of 1 million women born in 
1960 throughout their lifetimes. We compared no screening strategy to eight mam-
mography screening strategies that consisted of a combination of different initiation 
age (40 vs. 50), cessation age (74 vs. 79), and frequency (annual vs. biennial) of 
screening. Upon identifying the most cost-effective strategy, we then applied probabi-
listic sensitivity analyses (PSA) to explore the impact of different patterns of treatment 
dissemination on the cost-effectiveness of screening. RESULTS: At the societal will-
ingness-to-pay (WTP) of $50,000 per life year (LY) gained and with the dissemination 
pattern prior to the availability of trastuzumab, the most cost-effective screening 
strategy was biennial screening for women aged 50–74. The probability that this 
strategy was more cost-effective than the no screening strategy was 0.43, followed by 
biennial screening 50–79 (prob = 0.41), biennial screening 40–79 (prob = 0.08), and 
biennial screening 40–74 (prob = 0.04). At a WTP of $100,000/LY, the probabilities 
increased to 0.89, 0.87, 0.76, and 0.72, respectively. Results from the PSA indicated 
that when adding trastuzumab to the base case dissemination pattern, the probability 
that the biennial screening 50–74 strategy was more cost-effective than the no screen-
ing strategy at a WTP of $100,000/LY decreased from 0.89 to 0.83, and the probabil-
ity further reduced to 0.60 if the optimal dissemination pattern (e.g., all patients with 
HER2 overexpression received trastuzumab) was achieved. CONCLUSIONS: The 
ﬁnding that improvements in treatment dissemination may paradoxically lead to a 
reduction in the cost-effectiveness of screening suggests that identifying and designing 
cost-effective strategies to allocate health care resources across the continuum of 
cancer care is likely to yield higher gains.
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USE OF LATENT VARIABLE AND SURVIVAL MODELING TO ESTIMATE 
THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES AND 
PROGRESSION-FREE SURVIVAL IN MALIGNANT PLEURAL 
MESOTHELIOMA
Hackshaw MD1, Boye ME2, West TM2, Prehn AW1
1Walden University, Minneapolis, MN, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: The purpose of this study was to conduct joint modeling of latent 
growth curve models (LGCMs) for patient-reported outcomes (PROs) and survival 
models for progression-free survival (PFS) to estimate their association in previously-
treated patients with advanced malignant pleural mesothelioma (MPM). METHODS: 
Post-hoc analyses were conducted on PRO and PFS data collected from 243 patients 
in a phase III randomized controlled trial of best supportive care (BSC) versus peme-
trexed-plus-BSC. PFS was a secondary end point in the original study; PRO data were 
collected using the Lung Cancer Symptom Scale (LCSS). LGCMs were constructed for 
the nine LCSS items including a treatment covariate; PFS was then regressed onto the 
growth factors of each LCSS item. RESULTS: There were no statistically signiﬁcant 
changes in PRO scores over time as determined by the slope coefﬁcient of the LGCMs. 
Statistically signiﬁcant associations were found between PFS and the latent growth 
factors (intercepts and slopes) of appetite loss, cough, dyspnea, symptom distress, and 
interference with activity level (p < .05). PFS was signiﬁcantly associated with the 
intercept of pain (p < .001), and the slope of global quality of life (p < .001) from the 
LGCMs; no growth factors were associated with fatigue or treatment. The joint 
hemoptysis model did not converge therefore the association between PFS and hemop-
tysis cannot be assessed. CONCLUSIONS: Joint modeling with PFS accounted for 
censoring of LGCM observations and increased our ability to estimate latent growth 
factors. This provided further insight into the meaningfulness and signiﬁcance of PFS 
by allowing more efﬁcient estimation of patient symptom levels that were associated 
with the progression-free disease interval. Application of these methods can help MPM 
patients, caregivers, providers, and payers to make more informed health care deci-
sions. Future research in other cancers is needed to determine if these ﬁndings are 
generalizable.
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OBJECTIVES: To deﬁne resources and procedures to set the direct medical costs of 
treatment of metastatic breast cancer (MBC) after anthracyclines and taxanes failure 
from the Mexican public health system perspective. METHODS: The unitary costs of 
chemotherapy, surgery, radiotherapy and hormonal therapy were obtained trough 
quantiﬁcation the consumption of health care resource reported in 587 clinical ﬁles 
of patients with advanced breast cancer patients after failure to anthracyclines and 
taxanes with at least two years follow-up treated at three tertiary public hospitals in 
Mexico: Hospital de Oncología del Centro Médico Siglo XXI del Instituto Mexicano 
del Seguro Social (SigloXXI) (47%), Instituto Nacional de Cancerología (INCAN) 
(42%) and Centro Universitario contra el Cáncer (CUCC) (11%). All costs (drugs, 
services and procedures) were obtained from institutional sources and expressed in 
2009 US$. RESULTS: The mean unitary cost of surgery at the SigloXXI (n = 26) is 
US$2177.31 ($1658.31-$2696.31), at the CUCC (n = 16) US$3060.14 ($2548.68-
$3571.60), and at the INCan (n = 106) US$2288.36 ($1945.56-$2631.16). The 
radiotherapy (at least 5 sessions) at the SigloXXI (n = 133) is US$755.90 ($696.59-
$815.20), CUCC (n = 31) US$910.28 ($728.20-$1092.36), INCan (n = 136) 
US$1128.13 ($1004.87-$1251.40). The hormonotherapy cost (at least 3 months) is 
SigloXXI (n = 107) US$1640.19 ($1154.73-$2125.64), CUCC (n = 30) US$932.40 
($528.49-$1336.31), INCan (n = 102) US$1887.09 ($1396.56-$2377.62). The mean 
chemotherapy cost (all regimens included for at least 3 cycles) at the SigloXXI (n = 
213) US$9278.98 ($8097.55-$10,460.42), CUCC (n = 43) US$6174.23 ($1962.75-
$10,385.71), INCan (n = 200) US$8212.42 ($6876.50-$9548.34). CONCLUSIONS: 
The treatment costs vary widely within every center, as result of the clinical practice 
variability, but seem consistent between centers included in this analysis with no 
signiﬁcant statistical differences.
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USING QALYS IN CANCER: WHAT ARE THE METHODOLOGICAL 
LIMITATIONS?
Wang Q1, Shah K2
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OBJECTIVES: This presentation will examine how well the quality-adjusted life year 
(QALY) captures the health gains generated by cancer treatments, with particular 
focus on the methods for constructing QALYs preferred by the National Institute for 
Health and Clinical Excellence (NICE), the organisation responsible for providing 
advice on the cost-effective use of health care resources in England and Wales. 
METHODS: Comprehensive literature review; The published literature relating to 
QALYs and cancer will be reviewed, with data obtained using a keyword search of 
the MEDLINE database and a hand search of articles written by leading researchers 
in the subject area. RESULTS: Three key issues are identiﬁed and will be discussed. 
First, the EQ-5D, a widely used measure of health-related quality of life in adults, has 
been found to be relatively insensitive to changes in health status of cancer patients. 
Second, the time trade-off, a widely used technique for estimating the values of health 
states, involves making assumptions that are likely to be violated in end-of-life sce-
narios. Third, the practice of using valuations of members of the general population, 
as recommended both by NICE and the US Public Health Service Panel, is problematic 
because such individuals typically display a misunderstanding of what it is really like 
for patients to live with cancer. Thus, it is clear that because of the way in which it 
is constructed, the QALY shows important limitations in terms of its ability to accu-
rately capture the value of the health gains deemed important by cancer patients. 
CONCLUSIONS: The presentation will conclude by proposing a research agenda for 
addressing these limitations.
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CLINICAL, ECONOMIC, AND HUMANISTIC BENEFITS OF  
A RHEUMATOID ARTHRITIS DISEASE THERAPY  
MANAGEMENT PROGRAM
Stockl KM, Shin J, Harada AS, Lew HC, Solow BK, Curtis BS
Prescription Solutions, Irvine, CA, USA
OBJECTIVES: To evaluate clinical, economic, and humanistic outcomes of a rheu-
matoid arthritis (RA) disease therapy management (DTM) program designed to 
improve self-management of injectable RA medication therapy. METHODS: Patient-
reported outcomes among patients (N = 371) completing a 7-month RA DTM 
program were compared from Month 0 to Month 6 using the Short Form (SF)-12®, 
Work Productivity Activity Impairment (WPAI), and Health Assessment Question-
naire (HAQ)-Disability (DI)© tools. Propensity scoring was used to match these 
patients with two non-DTM cohorts who ﬁlled injectable RA medications at specialty 
or retail pharmacies (N = 244 in each cohort). Adherence to injectable RA medication 
was measured by calculating the medication possession ratio (MPR) over an 8-month 
post-period. Among the subgroup of patients with medical claims data in the DTM 
(N = 46), specialty (N = 55) and retail (N = 32) cohorts, changes in pharmacy, medical, 
and total health care costs per patient per month (PPPM) were compared from the 
pre- and post-periods. RESULTS: SF-12 physical component scores signiﬁcantly 
increased by 1.1 points (p = 0.048), SF-12 mental component scores were not changed, 
WPAI work productivity decreased by 10.8% (p = 0.045), and HAQ-DI scores sig-
niﬁcantly improved by 0.08 points (p = 0.0003). DTM patients had signiﬁcantly higher 
medication adherence compared with specialty or retail pharmacy patients (MPR 0.91, 
0.83, and 0.61, respectively; p < 0.0001). Median pharmacy costs increased by $25.78, 
$20.39, and $7.27 PPPM, respectively (p = 0.001 for DTM vs. retail). Total health 
care costs were similar across comparison cohorts (median increases of $23.61, 
$22.48, and $27.22 PPPM, respectively). CONCLUSIONS: Patients completing the 
RA DTM program experienced increased medication adherence and improvements in 
SF-12 physical component and HAQ-DI scores, but did not have improved SF-12 
